U.S. IV Infusion Products Market to Surpass US$ 10,238.5 Million by 2028

U.S. IV Infusion Products Market, by Product Type (Cannulation (Needles and Catheter), IV Infusion Pump (Gravity Infusion Devices, Volumetric Pump, Syringe Pump, and Others), Infusion Lines (Set) (Gravity IV Set, Gravity IV Set W/Needle Free Connector, and Pump IV Set), and Others), by Stop Cock Type (3 Way Stopcock, Vacuum Stopcocks, Burette Stopcocks, and Others), by Needle Free Connector (Standalone Connectors and Needle-free Extension Sets), by Infusion Site (Peripheral IV, Medline IV, and Central IV), by Application (Pain Management, Antibiotic/Antiviral, Chemotherapy, and Others), and by End User (Ambulatory Surgical Centers, Clinics, Home Care Settings, Hospitals, and Others), is estimated to be valued at US$ 7,885.4 million in 2021, and is expected to exhibit a CAGR of 3.8% during the forecast period (2021-2028).

The rising number of product launches or approvals is expected to drive growth of the U.S. IV infusion products market during the forecast period. For instance, on June 20, 2018, Teleflex Inc. attended World Congress on Vascular Access 2018 in Copenhagen, Denmark and launched Arrowg+ard Blue Advance peripherally inserted central catheters (PICC).The product reduces the risk of catheter-related complications such as occlusion, phlebitis, and fibrin sheath accumulation on catheter surfaces.

Moreover, increasing acquisitions, partnerships, and collaborations between market players is expected to propel growth of the U.S. IV infusion products market during the forecast period. For instance, on October 06, 2016, ICU Medical Inc., a global firm that develops, manufactures, and sells medical technology used in vascular therapy, oncology, and critical care, announced the acquisition of Hospira Infusion Systems, Pfizer's global infusion therapy division. Hospira Infusion Systems business include IV pumps, systems, and devices, when coupled with ICU Medical's existing assets, would make Hospira a top pure-play infusion therapy firm.

U.S. IV Infusion Products Market- Impact of Coronavirus (COVID – 19) Pandemic

The COVID-19 pandemic has affected several markets across the globe. The COVID-19 pandemic has affected the demand and supply of healthcare products in three main ways; by directly affecting the production and demand; by creating disruptions in distribution channels; and due to its financial impact on firms and financial markets.

However, the coronavirus (COVID-19) pandemic is expected to drive growth of the U.S. IV infusion products market during the forecast period, owing to increasing demand for infusion pumps in COVID-19 patients and issuance of guidelines to increase the availability of infusion pumps. For instance, on April, 05, 2020, during the COVID-19 pandemic, the U.S. Food and Drugs Administration (FDA) issued a guideline to help improve the availability and remote capabilities of infusion pumps and their accessories for health care practitioners. According to the new guidance document, the U.S. FDA will not object to limited changes to the indications, functionality, hardware, software, design, or materials of devices used to support patients requiring continuous infusion therapy. The policy applies when a device is modified in a way that would typically necessitate a new 510(k) premarket submission.

Browse 20 Market Data Tables and 54 Figures spread through 245 Pages and in-depth TOC on U.S. IV Infusion Products Market, by Product Type (Cannulation (Needles and Catheter), IV Infusion Pump (Gravity Infusion Devices, Volumetric Pump, Syringe Pump, and Others), Infusion Lines (Set) (Gravity IV Set, Gravity IV Set W/Needle Free Connector, and Pump IV Set), and Others), by Stop Cock Type (3 Way Stop Cock, Vacuum Stopcocks, Burette Stopcocks, and Others), by Needle Free Connector (Standalone Connectors and Needle-free Extension Sets), by Infusion Site (Peripheral IV, Medline IV, and Central IV), by Application (Pain Management, Antibiotic/Antiviral, Chemotherapy, and Others), and by End User (Ambulatory Surgical Centers, Clinics, Home Care Settings, Hospitals, and Others)

To know the latest trends and insights prevalent in the U.S. IV Infusion Products Market, click the link below:

 https://www.coherentmarketinsights.com/market-insight/us-iv-infusion-products-market-4700

Key Takeaways of the U.S. IV Infusion Products Market:

• The U.S. IV infusion products market is expected to exhibit a CAGR of 3.8% over the forecast period (2021-2028). Increasing research and development activities, rising product launches and approvals, inorganic activities such as collaborations, agreements, acquisitions, and others are expected to drive growth of the U.S. IV infusion products market over the forecast period. For instance, on April 4, 2017, BD (Becton, Dickinson and Company) acquired Caesarea Medical Electronics (CME), an infusion pump systems manufacturer. This acquisition added ambulatory, home, and specialty acute care infusion pumps to BD’s portfolio.
• Some of the major players operating in the U.S. IV infusion products market include AngioDynamics Inc., Kimal, Terumo Corporation, Teleflex Inc., Becton, Dickinson and Company,  Cook Group, Nipro Corporation, ZOLL Medical Corporation, B. Braun Medical Inc., AdvaCare Pharma, PL Medical Co., LLC, Greiner Bio-One International GmbH, EMED Technologies Corporation, CODAN Companies, and Smiths Group plc.